Please login to the form below

Not currently logged in
Email:
Password:

Rydapt

This page shows the latest Rydapt news and features for those working in and with pharma, biotech and healthcare.

FDA fast-tracks Astellas' Rydapt rival

FDA fast-tracks Astellas' Rydapt rival

FDA fast-tracks Astellas' Rydapt rival. AML treatment gilteritinib is currently involved in four phase III trials. ... Astellas Pharma has claimed a fast-track designation in the US for its FLT3 inhibitor gilteritinib, a drug that could rival

Latest news

  • Novartis gets EU nod for leukaemia drug Rydapt Novartis gets EU nod for leukaemia drug Rydapt

    Novartis gets EU nod for leukaemia drug Rydapt. The FLT3 inhibitor adds to its US approval in AML. ... The EMA has cleared Rydapt (midostaurin) for use alongside chemotherapy in patients with newly-diagnosed adults with AML whose cancer cells carry the

  • Astellas extends phase III programme for Rydapt rival gilteritinib Astellas extends phase III programme for Rydapt rival gilteritinib

    Astellas extends phase III programme for Rydapt rival gilteritinib. Japanese group hopes its AML drug will soon compete with Novartis' recently-approved treatment. ... Astellas has started a fourth phase III trial of acute myeloid leukaemia (AML) drug

  • Celgene, Agios get FDA OK for leukaemia drug Idhifa Celgene, Agios get FDA OK for leukaemia drug Idhifa

    Celgene, Agios get FDA OK for leukaemia drug Idhifa. Duo’s drug becomes first new AML therapy since Novartis' Rydapt. ... It has launched the drug immediately on approval, becoming the first new drug specifically approved for AML by the FDA since

  • CHMP backs three immuno-oncology drugs for solid tumours CHMP backs three immuno-oncology drugs for solid tumours

    The crop of new immuno-oncology positive opinions was also accompanied by recommendations for targeted cancer drugs, including Novartis' Rydapt (midostaurin) which is now on course to become the treatment for

  • Novartis' Rydapt approval ends long AML therapy drought Novartis' Rydapt approval ends long AML therapy drought

    Novartis' Rydapt approval ends long AML therapy drought. Targeted blood cancer drug wins US licence from the FDA. ... Novartis' drug may not have the FLT3 inhibitor market to itself for long however as competition to Rydapt is heading down the pipeline.

More from news
Approximately 3 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Quintiles

With a network of more than 27,000 employees conducting business in approximately 100 countries, we have helped develop or commercialize...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics